Literature DB >> 11713802

Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

J T Holmlund1, B P Monia, T J Kwoh, F A Dorr.   

Abstract

Antisense oligonucleotides offer the promise of therapeutic effect with few toxic effects, by virtue of their high selectivity. Preclinical studies have provided evidence of antisense effects in vitro and in vivo, and phase I clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides for the treatment of cancer. This review summarizes the status of development of three anticancer antisense oligonucleotides from ISIS Pharmaceuticals.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11713802

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  10 in total

Review 1.  Anticancer drug targets: growth factors and growth factor signaling.

Authors:  J B Gibbs
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  CHARMM force field parameters for simulation of reactive intermediates in native and thio-substituted ribozymes.

Authors:  Evelyn Mayaan; Adam Moser; Alexander D MacKerell; Darrin M York
Journal:  J Comput Chem       Date:  2007-01-30       Impact factor: 3.376

3.  Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing.

Authors:  Jessica L Childs; Matthew D Disney; Douglas H Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

4.  Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.

Authors:  Judy Wang; Paul Chen; Marko Mrkobrada; Meiduo Hu; Katherine A Vallis; Raymond M Reilly
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-15       Impact factor: 9.236

5.  Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.

Authors:  Martin Bartsch; Alida H Weeke-Klimp; Dirk K F Meijer; Gerrit L Scherphof; Jan A A M Kamps
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

6.  Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles.

Authors:  Kirill A Afonin; Mathias Viard; Ioannis Kagiampakis; Christopher L Case; Marina A Dobrovolskaia; Jen Hofmann; Ashlee Vrzak; Maria Kireeva; Wojciech K Kasprzak; Vineet N KewalRamani; Bruce A Shapiro
Journal:  ACS Nano       Date:  2014-12-18       Impact factor: 15.881

7.  Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

Authors:  Immacolata Scognamiglio; Maria Teresa Di Martino; Virginia Campani; Antonella Virgilio; Aldo Galeone; Annamaria Gullà; Maria Eugenia Gallo Cantafio; Gabriella Misso; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia; Giuseppe De Rosa
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

8.  The preparation of new phosphorus-centered functional groups for modified oligonucleotides and other natural phosphates.

Authors:  Arnaud Gautier; Chrystel Lopin; Goulnara Garipova; Olivier Dubert; Irina Kalinina; Carmen Salcedo; Sébastien Balieu; Stéphane Glatigny; Jean-Yves Valnot; Géraldine Gouhier; Serge R Piettre
Journal:  Molecules       Date:  2005-09-30       Impact factor: 4.411

9.  Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells.

Authors:  Mollie S Schubert; Edward Cedrone; Barry Neun; Mark A Behlke; Marina A Dobrovolskaia
Journal:  J Cytokine Biol       Date:  2018-01-29

Review 10.  Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.

Authors:  Marina A Dobrovolskaia; Mark Bathe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.